Dendritic Nanotechnologies and Lumera Sign Joint Research Agreement
News Nov 11, 2005
Dendritic Nanotechnologies Inc. (DNT) and Lumera have entered into a joint research agreement to co-develop certain proprietary surface chemistries suitable for specific applications of Lumera's label-free array reader, ProteomicProcessor™.
Under the terms of this agreement, DNT will build chemistries on proprietary Lumera surfaces, focusing efforts on using their expertise and patent holdings in the area of dendrimers.
Lumera will use their proprietary instrument designs and biological systems to test and evaluate the dendrimer-based approaches.
It is expected that the combined expertise of Lumera in optically active polymers, defined surfaces and label-free detection systems, and the dendrimer expertise of Dendritic Nanotechnologies, will result in performance features and benefits for proteomic applications.
“This research agreement with Lumera is an important milestone for DNT since it represents one of the first commercial applications of our recently announced Priostar dendrimers,” said Robert Berry, DNT's chief executive officer.
DNT's dendrimer technology is called Priostar™ and is designed to offer an advantage over other precision nanostructures by reducing the complexity and duration of the synthesis process.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019